Ambrx Provides Safety and Efficacy Data from Ongoing Phase :

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose...

Related Keywords

United States , Madrid , Spain , Danielj Oconnor , Shawn Zhang , Karissa Cross , Scottt Tagawa , John Shen , David Mills , Mike Moyer , European Society Of Medical Oncology , Ambrx Biopharma Inc , Nasdaq , Scripps Research Institute , Lifesci Communications , Medical Oncology , Key Opinion Leader , First In Human Phase , Chief Executive Officer , Prostate Cancer Poster Session , Prostate Cancer Poster , Basic Science Poster Session , Basic Science Poster , Ambrx Biopharma , Private Securities Litigation Reform Act , Current Report , Nasdaq Amam ,